- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02127749
The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia (MISSION-2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Sepsis ranks among the top ten leading causes of death worldwide. Most nonsurvivors die in a state of immunosuppression. The gut microbiota exerts numerous beneficial functions in the host response against infections. Gut flora components express microorganism-associated molecular patterns (MAMPs) such as lipopolysaccharide (LPS), which are recognized by pattern recognition receptors (PRRs) expressed by neutrophils and macrophages. MAMPs from the intestinal microbiota constitutively translocate to the circulation and prime bone marrow derived neutrophils via PRRs. Antibiotic treatment, which is standard of care for all patients with sepsis, depletes the gut microbiota and leads to a diminished release of MAMPs and other bacteria derived products. This causes diminished priming of systemic immunity, which may attribute to sepsis associated immunosuppression and an increased susceptibility to invading bacteria.
Objective: To investigate the role of the gut microbiota in the systemic priming of immune effector cells during human endotoxemia
Study design: Randomized, between- and within-subject-controlled intervention study in human volunteers
Intervention: All subjects will receive lipopolysaccharide (endotoxin; 2 ng/kg bodyweight) intravenously to induce experimental endotoxemia. Eight subjects will be pretreated with broad spectrum antibiotics (ciprofloxacin, vancomycin, metronidazole) for seven days (washout period of 36 hours before endotoxemia), in order to deplete the gut microbiota. Blood and faeces will be sampled before, during and after endotoxemia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Academic Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy
- Male between 18 and 35 years of age
- Capable of giving written informed consent
- Chemistry panel without any clinically relevant abnormality
- Normal defecation pattern
Exclusion Criteria:
- Major illness in the past 3 months or any chronic medical illness
- History of any type of malignancy
- Past or current gastrointestinal disease
- Known positive test for hepatitis C antibody, hepatitis B surface antigen or HIV antibody 1 or 2
- Current or chronic history of liver disease
- Subject uses tobacco products
- History, within 3 years, of drug abuse
- History of alcoholism
- Any clinically relevant abnormality on the 12-lead ECG
- The subject has received an investigational product within three months
- Use of prescription or non-prescription drugs
- Use of antibiotics within 12 months
- Known allergy to antibiotics
- Subject has difficultly in donating blood or accessibility of a vein in left or right arm.
- Subject has donated more than 350 mL of blood in last 3 months
- Difficulty swallowing pills
- Body mass index more than 28
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control
Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously
|
Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
Other Names:
|
Experimental: Antibiotics
Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously
|
Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
Other Names:
ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cytokine production in blood
Time Frame: within 8 hours after LPS administration
|
within 8 hours after LPS administration
|
Collaborators and Investigators
Investigators
- Principal Investigator: W. J. Wiersinga, MD, PhD, Academic Medical Centre, Amsterdam
Publications and helpful links
General Publications
- Haak BW, Lankelma JM, Hugenholtz F, Belzer C, de Vos WM, Wiersinga WJ. Long-term impact of oral vancomycin, ciprofloxacin and metronidazole on the gut microbiota in healthy humans. J Antimicrob Chemother. 2019 Mar 1;74(3):782-786. doi: 10.1093/jac/dky471.
- Lankelma JM, Cranendonk DR, Belzer C, de Vos AF, de Vos WM, van der Poll T, Wiersinga WJ. Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study. Gut. 2017 Sep;66(9):1623-1630. doi: 10.1136/gutjnl-2016-312132. Epub 2016 Jun 15.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Sepsis
- Bacteremia
- Toxemia
- Endotoxemia
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Vancomycin
- Metronidazole
- Ciprofloxacin
Other Study ID Numbers
- NL45198.018.13 (Other Identifier: CCMO (Centrale Commissie voor Mensgebonden Onderzoek))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endotoxemia
-
Radboud University Medical CenterUMC UtrechtCompletedSepsis, Endotoxemia, ImmunosuppressionNetherlands
-
Petrovsky National Research Centre of SurgeryRecruitingMultiple Organ Dysfunction With Severe EndotoxemiaRussian Federation
-
Alteco Medical ABWithdrawnSuspected or Diagnosed Endotoxemia Casued by Gram-negative Bacteria
-
DaniscoCompleted
-
Ohio State UniversityCompletedMetabolic Syndrome | Metabolic EndotoxemiaUnited States
-
Iowa State UniversityCompleted
-
Radboud University Medical CenterMaastricht University Medical CenterCompleted
-
Radboud University Medical CenterCompleted
-
Radboud University Medical CenterCompleted
-
Radboud University Medical CenterCompleted
Clinical Trials on Endotoxin
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedAsthma | Rhinitis, Allergic, Perennial | Rhinitis, Allergic, SeasonalUnited States
-
University of Alabama at BirminghamAmerican Fibromyalgia Syndrome AssociationCompleted
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
University of California, Los AngelesNational Institute on Aging (NIA)RecruitingDepression | Inflammation | Anhedonia | Anxiety | AgingUnited States
-
University of California, Los AngelesCompleted
-
University of California, Los AngelesActive, not recruitingDepression | AnhedoniaUnited States
-
Michael Irwin, MDRecruitingDepression in Old AgeUnited States
-
Robert J Noveck, M.D.Foundation for the National Institutes of HealthCompleted
-
Aarhus University HospitalCompleted
-
Karolinska InstitutetThe Swedish Research Council; University of California, San Francisco; Swedish... and other collaboratorsCompletedSickness Behavior